Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Caroli P, De Giorgi U, Scarpi E, Fantini L, Moretti A, Galassi R, Celli M, Conteduca V, Rossi L, Bianchi E, Paganelli G, Matteucci F. Caroli P, et al. Among authors: fantini l. Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):348-354. doi: 10.1007/s00259-017-3866-2. Epub 2017 Nov 6. Eur J Nucl Med Mol Imaging. 2018. PMID: 29110067 Clinical Trial.
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.
Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Sansovini M, et al. Among authors: fantini l. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):490-499. doi: 10.1007/s00259-016-3533-z. Epub 2016 Oct 4. Eur J Nucl Med Mol Imaging. 2017. PMID: 27704193
Exploratory Analysis of 18F-3'-deoxy-3'-fluorothymidine (18F-FLT) PET/CT-Based Radiomics for the Early Evaluation of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.
Fantini L, Belli ML, Azzali I, Loi E, Bettinelli A, Feliciani G, Mezzenga E, Fedeli A, Asioli S, Paganelli G, Sarnelli A, Matteucci F. Fantini L, et al. Front Oncol. 2021 Jun 24;11:601053. doi: 10.3389/fonc.2021.601053. eCollection 2021. Front Oncol. 2021. PMID: 34249671 Free PMC article.
Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results.
Matteucci F, Mezzenga E, Caroli P, Di Iorio V, Sarnelli A, Celli M, Fantini L, Moretti A, Galassi R, De Giorgi U, Paganelli G. Matteucci F, et al. Among authors: fantini l. Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2189-2194. doi: 10.1007/s00259-017-3791-4. Epub 2017 Aug 11. Eur J Nucl Med Mol Imaging. 2017. PMID: 28801787
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.
Rocca A, Cortesi P, Cortesi L, Gianni L, Matteucci F, Fantini L, Maestri A, Giunchi DC, Cavanna L, Ciani R, Falcini F, Bagni A, Meldoli E, Dall'Agata M, Volpi R, Andreis D, Nanni O, Curcio A, Lucchi L, Amadori D, Fedeli A. Rocca A, et al. Among authors: fantini l. Ther Adv Med Oncol. 2021 Feb 9;13:1758835920985632. doi: 10.1177/1758835920985632. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33613693 Free PMC article.
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.
Sansovini M, Severi S, Ianniello A, Nicolini S, Fantini L, Mezzenga E, Ferroni F, Scarpi E, Monti M, Bongiovanni A, Cingarlini S, Grana CM, Bodei L, Paganelli G. Sansovini M, et al. Among authors: fantini l. Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):352. doi: 10.1007/s00259-016-3558-3. Eur J Nucl Med Mol Imaging. 2017. PMID: 27807661 No abstract available.
Non FDG PET.
Nanni C, Fantini L, Nicolini S, Fanti S. Nanni C, et al. Among authors: fantini l. Clin Radiol. 2010 Jul;65(7):536-48. doi: 10.1016/j.crad.2010.03.012. Clin Radiol. 2010. PMID: 20541653
77 results